| Dr. Willmar Schwabe Group |
|
| Advisory Board | Dr. Klaus-Peter Schwabe Dr. Wolf-Dietrich Schwabe Norbert Keller |
| Turnover 2009 | € 575 Mill. |
| International Share | 52 % |
| Research & Development Expenditure 2009 World-wide | € 29 Mill. (Group-wide) |
| Employees World-wide | Approx. 3700 (Group-wide) |
| Dr. Willmar Schwabe GmbH & Co. KG |
|
| Location | Willmar-Schwabe-Str. 4 76227 KARLSRUHE GERMANY |
| Executive Board | Dr. Dirk Reischig (Chairman) Prof. Dr. Michael Habs Dr. Rainer Oschmann |
| Employees | 727 |
| Product Range | Phytomedicines |
| Research & Development Focus | Plant-based Special Extracts |
| Dr. Willmar Schwabe World-wide |
|
|
Austria: Belgium: China: Czech Republic: Germany: Hungary: India: Loacker Remedia Mexico: Farmasa Schwabe Schwabe México |
Netherlands: Romania: Russia: Singapore: Slovakia: Spain: Switzerland: United Kingdom: Nature’s Way Enzymatic Therapy |
| Date: March 2010 | |
| Contact Address |
Dr. Willmar Schwabe GmbH & Co. KG Fax: +49 (0) 721 4005 – 202 |
Major study shows that long-term intake of Ginkgo biloba special extract EGb 761® protects against Alzheimer's disease
Read moreYou can change the Font Size here:
Font Size